Role of steroids in fungal rhinosinusitis
Reading File
Steroids play different roles depending on the type of fungal rhinosinusitis - they are used (cautiously) in allergic forms but are generally contraindicated in invasive forms. Let me pull detailed textbook content on this.
Searching sources...
Finding Sources
Finding Sources
Searching PubMed
steroids fungal rhinosinusitis treatment
Good hits. Now let me read the key sections in parallel.
Reading File
Reading File
Reading File
Good content retrieved. Let me now read the Scott-Brown AFRS management section and the antifungal agents section for more details on steroid use.
Reading File
Reading File
Now let me get the Scott-Brown Vol 1 AFRS management section for the oral corticosteroid protocols and K.J. Lee's section for more details.
Reading File
Finding Sources
Let me look at the detailed AFRS treatment section in Scott-Brown Vol 1 block 2, and also search for more detail on steroids in invasive FRS and the KJ Lee section.
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Reading File
I now have comprehensive information from multiple authoritative textbooks. Let me compile the final answer.
Role of Steroids in Fungal Rhinosinusitis
Fungal rhinosinusitis (FRS) is broadly classified into non-invasive (fungal ball, allergic fungal rhinosinusitis) and invasive (acute, chronic granulomatous, chronic non-granulomatous) forms. The role of steroids differs fundamentally between these categories.
1. Allergic Fungal Rhinosinusitis (AFRS) - The Primary Indication
AFRS is a Type I (and possibly Type III) hypersensitivity reaction to inhaled fungal antigens in atopic, immunocompetent individuals. The eosinophilic inflammatory cascade makes it the one form of FRS where steroids have a well-established and central role.
Rationale for Use
The underlying mechanism is an IgE-mediated hypersensitivity reaction (analogous to ABPA) producing eosinophilic mucin, nasal polyposis, and local inflammation. Steroids suppress this eosinophilic/allergic cascade. Patients typically show an excellent response to oral corticosteroids but not antibiotics - a clinical clue that helps differentiate AFRS from bacterial CRS. - Scott-Brown's Otorhinolaryngology Vol 1, p.261
A. Oral (Systemic) Corticosteroids
Perioperative use: Systemic steroids are started perioperatively (usually beginning around the time of surgery), then tapered over several days to weeks. They help reduce mucosal oedema, shrink polyps, and improve surgical access. They may also aid disease remission post-surgery. - Cummings Otolaryngology, p.892
Post-operative use: Gan et al. (2014) published an evidence-based review that recommends post-operative systemic steroids (Grade B evidence from four studies, including two level 2b and two level 4 studies; n=76 AFRS patients). These studies reported a significant reduction in post-operative mucosal disease and inflammatory markers. - Scott-Brown's Otorhinolaryngology Vol 1, p.262
A prospective, randomized, placebo-controlled trial by Rupa et al. (2010) compared oral prednisolone vs. placebo post-operatively (n=12 each arm) and concluded that post-operative oral steroid in a tapering dose produces significant subjective and objective improvement in AFRS patients. - Scott-Brown's Otorhinolaryngology Vol 1, p.262
Limitations: High-dose corticosteroids carry significant side effects (hyperglycemia, bone loss, adrenal suppression), and disease recurrence may occur after cessation of systemic steroids. - Cummings Otolaryngology, p.892
B. Topical (Intranasal) Corticosteroids
Topical nasal steroids achieve effective drug concentration at the sinonasal mucosa with few systemic side effects and are recommended by Gan et al. (Grade B). They are used in nasal saline irrigations post-operatively and provide long-term maintenance without the side-effect burden of systemic steroids.
However, the evidence is not uniformly strong: one RCT comparing post-operative topical nasal steroids + nasal douching vs. nasal douching alone vs. nasal douching + itraconazole showed no significant benefit at 6 months for topical nasal steroids, though the study had significant limitations. - Scott-Brown's Otorhinolaryngology Vol 1, p.262
Despite this, post-operative topical corticosteroid therapy mixed with saline irrigations is widely advocated to reduce dependence on systemic steroids and prevent relapse. - Cummings Otolaryngology, p.892
Summary of Steroid Regimen in AFRS
| Phase | Route | Purpose |
|---|---|---|
| Perioperative | Oral (tapering) | Reduce polyp/mucosal burden, improve surgical field |
| Post-operative (short-term) | Oral (tapering) | Reduce recurrence, control residual mucosal disease |
| Post-operative (long-term) | Topical intranasal (+ saline irrigation) | Maintenance, minimize systemic steroid exposure |
2. Fungal Ball (Mycetoma) - No Role for Steroids
The treatment is purely surgical: complete removal of fungal debris by ESS with large antrostomy/ostioplasty and thorough irrigation. No further medical therapy (including steroids) is required in most cases after successful debridement. - Cummings Otolaryngology, p.875
3. Invasive Fungal Rhinosinusitis (IFRS) - Steroids are Contraindicated
IFRS occurs almost exclusively in severely immunocompromised patients (uncontrolled diabetes, haematological malignancies, solid organ transplant recipients, prolonged neutropenia). The treatment triad is:
- Reversal of the underlying immunodeficiency (the single most important factor for survival)
- Systemic antifungal therapy (broad-spectrum initially, then culture-directed)
- Aggressive surgical debridement of all avascular and necrotic tissue until healthy bleeding tissue is reached
Steroids have no role here and are potentially harmful. They would further suppress the already-compromised immune system, worsen neutrophil function, and promote uncontrolled fungal spread. If the immunocompromised status is profound and irreversible, even surgical treatment is unlikely to be successful. The prognosis in IFRS remains grim despite optimal treatment. - Cummings Otolaryngology, p.875-876
4. Interaction with Antifungals in AFRS
In AFRS patients refractory to surgery and oral/topical steroids, itraconazole (200-400 mg daily in divided doses for up to 6 months) can be combined with steroids to:
- Reduce the fungal antigen load driving the hypersensitivity
- Reduce dependence on oral steroids
- Prevent disease recurrence and the need for revision surgery
One cohort of 139 AFRS patients treated with high-dose post-operative itraconazole combined with oral and topical steroids showed a significant reduction in the need for revision surgery. - Scott-Brown's Otorhinolaryngology Vol 1, p.335
5. Immunotherapy as a Steroid-Sparing Strategy
In AFRS, allergen immunotherapy (subcutaneous) has Level C evidence (two case-control studies + three prospective case series) showing:
- Reduced reliance on post-operative steroids
- Reduced post-operative exacerbations
- Lower revision surgery rates (11.1% with IT vs. 33% without IT, Bassichis et al.)
Immunotherapy does not appear to cause unusual side effects or immune complex formation in AFRS patients. It is especially useful for reducing long-term steroid burden. - Scott-Brown's Otorhinolaryngology Vol 1, p.262
Key Takeaways
- AFRS = steroids are central: oral perioperatively + post-op taper, then maintain on topical steroids. The disease is essentially driven by eosinophilic hypersensitivity, not infection, so immune suppression is appropriate.
- Fungal ball = no steroids needed after surgical clearance.
- Invasive FRS = steroids are contraindicated - they worsen immunosuppression and promote uncontrolled fungal invasion.
- Steroid side effects and recurrence after cessation are ongoing concerns in AFRS; immunotherapy and antifungals serve as steroid-sparing adjuncts.
- The 2025 systematic review by Shafik et al. (PMID 40270102) on post-operative oral corticosteroids after sinus surgery for CRS provides the most recent high-level evidence on this topic, though it covers CRS broadly rather than AFRS specifically.
Antacids in first trimester
Reading File
This is a Special Population query (pregnancy - first trimester) - flagging for Step 3e. Let me search in parallel across the library and PubMed.
Searching sources...
Finding Sources
Finding Sources
Searching PubMed
antacids pregnancy first trimester safety
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
antacids heartburn pregnancy
Reading File
Reading Article
PMID: 36107559
Reading Article
PMID: 35343261
Excellent - I now have comprehensive, authoritative information. Let me compile the final answer.
Antacids in the First Trimester of Pregnancy
Why Antacids Are Needed in Pregnancy
Heartburn (pyrosis) and acid reflux are among the most common GI complaints in pregnancy. Symptoms may actually begin in the first trimester and typically worsen as pregnancy progresses, peaking in the third trimester. By term, 50-80% of pregnant patients experience heartburn. The key mechanisms are:
- Hormonal effects: Progesterone relaxes smooth muscle, reducing lower esophageal sphincter (LES) tone and slowing gastric emptying
- Mechanical effects: The enlarging uterus increases intra-abdominal pressure and compresses the stomach
- Nausea and vomiting in early pregnancy often overlap with acid symptoms, making GERD easy to underdiagnose
The first trimester is also when organogenesis is most active (weeks 3-8), making teratogenic safety the primary concern when choosing any drug. - Sleisenger and Fordtran's GI and Liver Disease
Antacids: First-Line Pharmacologic Therapy
After lifestyle and dietary modification (small frequent meals, elevating the head of bed, avoiding triggers such as spicy/fatty foods, caffeine, and lying down after meals), liquid antacids are the first-line pharmacologic therapy for GERD in pregnancy. The FDA also endorses antacids as first-line for heartburn in pregnancy. - Garg et al., J Int Med Res 2022 (PMID 35343261)
A step-up approach is recommended:
- Lifestyle modification
- Antacids (first pharmacologic step - Grade A evidence for calcium-containing antacids)
- Sucralfate (1 g orally three times daily - Grade C)
- H2-receptor antagonists (e.g., ranitidine - Grade B)
- PPIs - reserved for refractory cases (Grade C)
- Altuwaijri, Medicine 2022 (PMID 36107559)
Individual Antacid Classes: Safety Profile in the First Trimester
1. Calcium Carbonate (e.g., Tums, Digene)
- Preferred choice in pregnancy - Grade A recommendation
- Safe in the first trimester: No teratogenic risk established
- Provides the added benefit of supplementing calcium requirements in pregnancy
- Avoid very high doses chronically - risk of hypercalcemia and milk-alkali syndrome (rare)
2. Magnesium Hydroxide/Magnesium Trisilicate (e.g., Milk of Magnesia, Gelusil)
- Generally safe in the first trimester - no known teratogenicity
- Caution: Avoid in the late third trimester - high-dose magnesium may theoretically impair uterine contractions (tocolytic effect) and delay labor
- Magnesium trisilicate: some older animal data suggested fetal nephrolithiasis and respiratory distress with prolonged high-dose use; clinical significance uncertain
- Short-term, low-dose use in the first trimester is considered acceptable
3. Aluminum Hydroxide (e.g., Alu-gel, Maalox combination)
- Generally used in combination formulations
- Large doses may cause constipation (problematic in pregnancy) and theoretically interfere with phosphate absorption
- Limited human teratogenicity data, but no established adverse fetal effects
- Avoid large doses or prolonged monotherapy
4. Sodium Bicarbonate
- Avoid in pregnancy - especially the first trimester and throughout
- Causes systemic alkalosis, sodium overload, and fluid retention - worsens pregnancy-related edema and hypertension
- Can also cause rebound hyperacidity
- Not recommended at any stage of pregnancy
5. Sodium Alginate + Antacid combinations (e.g., Gaviscon)
- Alginate forms a physical raft over gastric contents, reducing reflux
- Considered safe in pregnancy - minimal systemic absorption
- Useful adjunct for reflux rather than just acid neutralization
Summary Table
| Antacid | First Trimester Safety | Key Concern |
|---|---|---|
| Calcium carbonate | Safe - preferred | Avoid excessive doses (hypercalcemia) |
| Magnesium hydroxide | Safe in 1st trimester | Avoid late 3rd trimester (impairs labor) |
| Aluminum hydroxide | Generally acceptable | Avoid high doses (constipation, phosphate) |
| Sodium bicarbonate | Avoid | Alkalosis, sodium overload, edema |
| Alginate combinations | Safe | Minimal absorption - good option |
Key Points
- Antacids are the first pharmacologic step for heartburn/GERD in pregnancy, including the first trimester; they act locally with minimal systemic absorption
- Calcium-containing antacids are preferred (Grade A evidence) - they are safe and provide a nutritional benefit
- Sodium bicarbonate should be avoided at all stages of pregnancy
- Magnesium-containing antacids are safe in the first trimester but should be stopped near term (third trimester)
- If antacids do not control symptoms, sucralfate then ranitidine (H2RA) can be added; PPIs are reserved for refractory cases
- No antacid has demonstrated teratogenicity in established human studies, but systemic agents (sodium bicarbonate, high-dose magnesium) carry indirect maternal risks that justify avoidance
Sources: Sleisenger and Fordtran's Gastrointestinal and Liver Disease; Altuwaijri, Medicine 2022 (PMID 36107559); Garg et al., J Int Med Res 2022 (PMID 35343261)
Rabeprazole and domperidone safe in first trimester ?
Both rabeprazole and domperidone warrant caution in the first trimester - rabeprazole is generally avoided as a first choice (though PPI class data is largely reassuring), while domperidone has more concerning safety signals. Let me pull the detailed evidence.
Searching sources...
Finding Sources
Finding Sources
Searching PubMed
proton pump inhibitor pregnancy first trimester safety
Reading File
Reading File
Reading Article
PMID: 37269915
Finding Sources
Reading File
Finding Sources
Searching PubMed
domperidone pregnancy safety fetal
Reading File
Finding Sources
I have sufficient information from multiple authoritative sources. Let me now compile the complete answer.
Rabeprazole and Domperidone in the First Trimester
Rabeprazole (PPI) in the First Trimester
Short Answer
Rabeprazole is not the first-line choice in pregnancy, but when a PPI is genuinely needed, it is considered acceptable. It carries FDA Pregnancy Category B - meaning animal studies show no fetal risk. The overall class data for PPIs is reassuring, but rabeprazole-specific human data is limited compared to omeprazole/lansoprazole.
What the Evidence Says
Class-level (all PPIs) safety:
The most recent 2023 systematic review and meta-analysis by Peron et al. (11 studies, 5,618 PPI-exposed pregnancies) found no significant increase in major congenital malformations with first-trimester PPI exposure (pooled OR 1.10, 95% CI 0.95-1.26; I² = 0%). No secondary outcomes (specific organ malformations) were significant either. - Peron et al., Reprod Toxicol 2023 (PMID 37269915)
Similarly, a large population study and two earlier meta-analyses found no significant risk of fetal malformations with first-trimester PPI use. - Sleisenger and Fordtran's GI and Liver Disease
Rabeprazole specifically:
- FDA Pregnancy Category B (unlike omeprazole, which is Category C due to embryotoxicity/fetotoxicity in animals)
- Multiple major references - Yamada's Gastroenterology, Rosen's Emergency Medicine, Creasy & Resnik's Maternal-Fetal Medicine - list rabeprazole as acceptable for use in pregnancy when clinically indicated
- Human data on rabeprazole specifically are limited (most pregnancy studies covered omeprazole and lansoprazole); there are insufficient data to evaluate it at the substance level individually
- Animal studies with rabeprazole did not show teratogenicity; however, there are reports of increased GI, hepatic, and thyroid cancers in rats/mice with PPIs as a class
One concern to note: An association between in-utero exposure to gastric acid suppressors (both PPIs and H2RAs) and childhood asthma/allergic disorders has been observed in registry studies, but this link is not established as causal and is of uncertain clinical significance. - Rosen's Emergency Medicine
Prescribing Guidance
PPIs should be reserved for patients with severe GERD/symptoms refractory to lifestyle changes, antacids, and H2-receptor antagonists. The step-up approach is:
- Lifestyle modification
- Antacids (calcium-containing preferred)
- Sucralfate
- H2RA (ranitidine/famotidine - well-studied, safer first-line)
- PPI - only if above measures fail
If a PPI is needed, lansoprazole or pantoprazole have more human pregnancy data than rabeprazole and are often preferred. Rabeprazole is not contraindicated but should only be used when the benefit clearly outweighs risk, and ideally not as the initial choice. - Yamada's Textbook of Gastroenterology; Creasy & Resnik's Maternal-Fetal Medicine
Domperidone in the First Trimester
Short Answer
Domperidone should generally be avoided in pregnancy, especially in the first trimester. It is not approved by the FDA for use in the US (not licensed), and regulatory agencies in Europe and elsewhere have raised safety concerns. There is very limited human pregnancy data, and its known cardiac risks (QT prolongation) are an additional concern.
Key Safety Concerns
1. QT Prolongation / Cardiac Risk:
Domperidone does not cross the blood-brain barrier (unlike metoclopramide), but it is associated with QT interval prolongation and may precipitate serious cardiac arrhythmias. This is a class effect concern that extends to fetal exposure, as the fetal cardiac conduction system is developing in the first trimester. - Sleisenger and Fordtran's GI and Liver Disease
2. Limited/Absent Human Pregnancy Data:
There is a striking absence of controlled human data on domperidone in pregnancy. It does not appear in major pregnancy drug safety tables in Creasy & Resnik (Maternal-Fetal Medicine), Yamada's Gastroenterology, or Rosen's Emergency Medicine - reflecting how little it is used or recommended in this context.
3. Regulatory Status:
- Not FDA-approved in the US (not available)
- European Medicines Agency (EMA) and Health Canada have issued restrictions on domperidone use in the general population due to cardiac risks; pregnancy use is even more restricted
- In India, where the combination tablet (rabeprazole + domperidone) is widely prescribed, its use in pregnancy is not recommended by major guidelines
4. What to Use Instead:
For nausea/vomiting and gastric motility in pregnancy:
- Pyridoxine ± doxylamine - safest, first-line for nausea/vomiting
- Metoclopramide - crosses the placenta but no association with adverse fetal outcomes across all stages of pregnancy (watch for extrapyramidal effects in the neonate if used near term); approved and widely used - Rosen's Emergency Medicine
- Ondansetron - human/animal data suggest low risk of birth defects; use with awareness of inconsistent data on cardiac anomalies/cleft palate risk
Bottom Line
| Drug | FDA Category | First Trimester Safety | Recommendation |
|---|---|---|---|
| Rabeprazole | B | Acceptable if PPI truly needed; limited substance-specific data | Prefer lifestyle + antacid + H2RA first; use PPI only for refractory cases |
| Domperidone | Not rated (not FDA approved) | Avoid - cardiac risks, no pregnancy safety data | Use metoclopramide or pyridoxine/doxylamine instead |
The combination tablet rabeprazole + domperidone (widely used in South Asia for dyspepsia/GERD) is not appropriate for use in the first trimester. The domperidone component makes this combination unsuitable, and the PPI component is only justified if symptoms are truly refractory. If acid suppression is needed, use the safest appropriate monotherapy with proper step-up logic.
Sources: Creasy & Resnik's Maternal-Fetal Medicine; Yamada's Gastroenterology; Rosen's Emergency Medicine; Sleisenger and Fordtran's GI and Liver Disease; Peron et al. Reprod Toxicol 2023 (PMID 37269915)
This is a shared conversation. Sign in to Orris to start your own chat.